← Back

PathMaker Neurosystems Inc. Announces Key Patent Issuance by US Patent and Trademark Office for Fundamental Technology Covering MyoRegulator™

Boston, MA (June 2, 2016) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, announced today that the United States Patent and Trademark Office (USPTO) has granted a fundamental patent (US Patent 9,283,391) covering our Company’s proprietary DoubleStim™ technology that forms the basis of our MyoRegulator™ system, a first-in-class non-invasive device now in human clinical trials for the treatment of muscle spasticity.

“We are pleased to see this latest patent issuance that supports PathMaker’s novel approach to the non-invasive treatment of chronic neuromotor conditions,” said Jake Maslow, J.D., Chief Intellectual Property Officer and Executive Vice President at PathMaker. “This issued US patent on our DoubleStim technology adds substantial coverage of our Company’s next‑generation non-invasive technology.”

DoubleStim utilizes a combination of simultaneous non-invasive spinal and peripheral stimulations. In our first implementation, the stimulation is directed to suppression of hyperexcitable spinal cord circuits that are involved in spasticity. DoubleStim technology is the basis of our MyoRegulator PM-2200 system, which is currently in development for the treatment of muscle spasticity in patients with stroke, cerebral palsy (CP), multiple sclerosis (MS), spinal cord injury (SCI), traumatic brain injury (TBI) and numerous other neurological conditions. These patients often have spasticity that severely limits motor control and impacts daily activities and quality of life. The MyoRegulator system addresses a major unmet need for safe and effective therapies that can non-invasively and durably reverse muscle spasticity. MyoRegulator was one of the first products accepted into United States Food and Drug Administration’s (USFDA) new Expedited Access Pathway intended for breakthrough products, and is now in IRB-approved human clinical trials at Northwell Health/Feinstein Institute for Medical Research. MyoRegulator is an investigational device and is limited by United States law to investigational use only.

“We are gratified to see this latest patent issuance, which covers the core technology underlying our Company’s first product, MyoRegulator,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Furthermore, this fundamental patent covers not only neuromotor applications of our technology, but also gives us broad coverage on next-generation approaches to autonomic neuromodulation.”

About PathMaker Neurosystems Inc.

PathMaker Neurosystems is a clinical-stage neuromodulation company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at www.pmneuro.com.